Literature DB >> 11773086

Precore stop mutant in HBeAg-positive patients with chronic hepatitis B: clinical characteristics and correlation with the course of HBeAg-to-anti-HBe seroconversion.

Chia-Ming Chu1, Chau-Ting Yeh, Ching-Song Lee, I-Shyan Sheen, Yun-Fan Liaw.   

Abstract

This study aimed to investigate the ratios of precore stop mutant (codon 28; TGG to TAG) to total viremia in 53 HBeAg-positive patients with chronic hepatitis B by amplification-created restriction site assays along the course of HBeAg-to-anti-HBe seroconversion. At baseline, 11% had exclusive wild-type hepatitis B virus (HBV), 15% had exclusively precore mutant, and 74% had mixed viral strains. Precore mutant ratios correlated little with age, sex, or HBV DNA levels (all P > 0.1), but correlated modestly with alanine aminotransferase (ALT) levels (P = 0.05). The intervals from presentation to anti-HBe seroconversion correlated significantly with ALT and precore mutant ratios in univariate analysis but with only precore mutant ratios in multivariate analysis (P = 0.003). Precore mutant ratios at baseline were significantly higher (P < 0.001) in six patients with persistent high viremia and ALT elevation after anti-HBe seroconversion (group 1) than in 47 with remission (group 2). All group 1 patients had exclusive precore mutant after anti-HBe seroconversion, as did only 14 (30%) of the group 2 patients (P = 0.003). Among group 2 patients, precore mutant ratios at baseline or after anti-HBe seroconversion showed no significant difference between 34 patients with sustained remission and 13 with relapse. Cirrhosis developed in 50% (5 of 10) of patients with precore mutant ratios >50% at baseline but only in 12% (5 of 43) of those with precore mutant ratios of <50% at baseline (P < 0.05). In conclusion, precore mutant of variable ratios was frequently detected in HBeAg-positive patients with chronic hepatitis B. Precore mutant ratios tended to correlate with ALT levels and anti-HBe seroconversion, but high precore mutant ratios were associated with persistent hepatitis after anti-HBe seroconversion and increased risk of cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11773086      PMCID: PMC120083          DOI: 10.1128/JCM.40.1.16-21.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  35 in total

1.  High genomic variability in the pre-C region of hepatitis B virus in anti-HBe, HBV DNA-positive chronic hepatitis.

Authors:  G Fiordalisi; E Cariani; G Mantero; A Zanetti; E Tanzi; M Chiaramonte; D Primi
Journal:  J Med Virol       Date:  1990-08       Impact factor: 2.327

2.  Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis.

Authors:  M R Brunetto; M M Giarin; F Oliveri; E Chiaberge; M Baldi; A Alfarano; A Serra; G Saracco; G Verme; H Will
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

3.  Absence of hepatitis B virus precore mutants in patients with chronic hepatitis B responding to interferon-alpha.

Authors:  J Xu; D Brown; T Harrison; Y Lin; G Dusheiko
Journal:  Hepatology       Date:  1992-06       Impact factor: 17.425

4.  A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group.

Authors:  R P Perrillo; E R Schiff; G L Davis; H C Bodenheimer; K Lindsay; J Payne; J L Dienstag; C O'Brien; C Tamburro; I M Jacobson; R Sampliner; D Feit; J Lefkowitch; M Kuhns; C Meschievitz; B Sanghvi; J Albrecht; A Gibas
Journal:  N Engl J Med       Date:  1990-08-02       Impact factor: 91.245

5.  Chronic active hepatitis with hepatitis B virus DNA and antibody against e antigen in the serum. Disturbed synthesis and secretion of e antigen from hepatocytes due to a point mutation in the precore region.

Authors:  Y Akahane; T Yamanaka; H Suzuki; Y Sugai; F Tsuda; S Yotsumoto; S Omi; H Okamoto; Y Miyakawa; M Mayumi
Journal:  Gastroenterology       Date:  1990-10       Impact factor: 22.682

6.  Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B.

Authors:  M R Brunetto; M Giarin; G Saracco; F Oliveri; P Calvo; G Capra; A Randone; M L Abate; P Manzini; M Capalbo
Journal:  Gastroenterology       Date:  1993-09       Impact factor: 22.682

7.  Precore mutant hepatitis B virus infection and liver disease.

Authors:  N V Naoumov; R Schneider; T Grötzinger; M C Jung; S Miska; G R Pape; H Will
Journal:  Gastroenterology       Date:  1992-02       Impact factor: 22.682

8.  High prevalence and heterogeneity of HBV preC mutants in anti-HBe-positive carriers with chronic liver disease in southern Italy.

Authors:  T Santantonio; M C Jung; S Miska; G Pastore; G R Pape; H Will
Journal:  J Hepatol       Date:  1991       Impact factor: 25.083

9.  The precore gene of the woodchuck hepatitis virus genome is not essential for viral replication in the natural host.

Authors:  H S Chen; M C Kew; W E Hornbuckle; B C Tennant; P J Cote; J L Gerin; R H Purcell; R H Miller
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

10.  Hepatitis B virus precore mutants are identical in carriers from various ethnic origins and are associated with a range of liver disease severity.

Authors:  R Tur-Kaspa; A Klein; S Aharonson
Journal:  Hepatology       Date:  1992-12       Impact factor: 17.425

View more
  20 in total

1.  Viral load, genotypes, and mutants in hepatitis B virus-related hepatocellular carcinoma: special emphasis on patients with early hepatocellular carcinoma.

Authors:  Chia-Ming Chu; Chen-Chun Lin; Shi-Ming Lin; Deng-Yn Lin; Yun-Fan Liaw
Journal:  Dig Dis Sci       Date:  2011-08-12       Impact factor: 3.199

2.  High level of hepatitis B virus DNA after HBeAg-to-anti-HBe seroconversion is related to coexistence of mutations in its precore and basal core promoter.

Authors:  Xiao-Mou Peng; Gui-Mei Huang; Jian-Guo Li; Yang-Su Huang; Yong-Yu Mei; Zhi-Liang Gao
Journal:  World J Gastroenterol       Date:  2005-05-28       Impact factor: 5.742

Review 3.  Current perspectives into the evaluation and management of hepatitis B: a review.

Authors:  Vignan Manne; Eric Gochanour; Kris V Kowdley
Journal:  Hepatobiliary Surg Nutr       Date:  2019-08       Impact factor: 7.293

4.  Clinical significance of hepatitis B virus (HBV) genotypes and precore and core promoter mutations affecting HBV e antigen expression in Taiwan.

Authors:  Chien-Hung Chen; Chuan-Mo Lee; Sheng-Nan Lu; Chi-Sin Changchien; Hock-Liew Eng; Chao-Min Huang; Jing-Houng Wang; Chao-Hung Hung; Tsung-Hui Hu
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

5.  Simultaneous detection of precore/basal core promoter mutations in hepatitis B virus using arrayed primer extension.

Authors:  Wai-Yan Ha; Chi-Chiu Lau; Patrick Y K Yue; Kaman K M Hung; Kelvin Chan; Siu-Hon Chui; Albert K K Chui; Wing-Cheong Yam; Ricky N S Wong
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

6.  Development of a molecular-beacon assay to detect the G1896A precore mutation in hepatitis B virus-infected individuals.

Authors:  Therese L Waltz; Salvatore Marras; Gemma Rochford; John Nolan; Eugenia Lee; Margherita Melegari; Henry Pollack
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

7.  A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen.

Authors:  Margaret T Chen; Jean-Noel Billaud; Matti Sällberg; Luca G Guidotti; Francis V Chisari; Joyce Jones; Janice Hughes; David R Milich
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-05       Impact factor: 11.205

8.  Comparison of complete sequences of hepatitis B virus genotype C between inactive carriers and hepatocellular carcinoma patients before and after seroconversion.

Authors:  Kiyoaki Ito; Yasuhito Tanaka; Michio Kato; Kei Fujiwara; Fuminaka Sugauchi; Tomoyuki Sakamoto; Noboru Shinkai; Etsuro Orito; Masashi Mizokami
Journal:  J Gastroenterol       Date:  2007-10-15       Impact factor: 7.527

9.  Influence of hepatitis B virus X and core promoter mutations on hepatocellular carcinoma among patients infected with subgenotype C2.

Authors:  Noboru Shinkai; Yasuhito Tanaka; Kiyoaki Ito; Motokazu Mukaide; Izumi Hasegawa; Yasuhiro Asahina; Namiki Izumi; Hiroshi Yatsuhashi; Etsuro Orito; Takashi Joh; Masashi Mizokami
Journal:  J Clin Microbiol       Date:  2007-07-25       Impact factor: 5.948

Review 10.  Hepatitis B virus variants.

Authors:  Watcharasak Chotiyaputta; Anna S F Lok
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-07-07       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.